Fenix Research Corporation — Department of Defense SBIR Phase I: CBD192-005

Fenix Research Corporation — SBIR Phase I award from Department of Defense.

Amount
$167,493
Agency
Department of Defense · Office for Chemical and Biological Defense
Program / Phase
SBIR · Phase I
Topic
CBD192-005
Solicitation
19.2
NAICS
Place of performance
CA
Period
2020-02-04 → 2020-08-04

Description

Infections of the central nervous system (CNS) are associated with brain swelling and increased cerebral blood volume, as well as focal cerebral perfusion deficits, variable levels of cerebral blood flow and cerebral vasculitis. The net result is increased intracranial pressure (ICP) along with significant risk of brain tissue herniation and ischemic syndromes. ICP monitoring is critical in the management of CNS infections. While invasive ICP measurements through direct access to the cranium using catheters provide reliable ICP measurements, it involves complicated clinical procedures, restricts patient mobility and risks of infection. The goal of the program is to develop and demonstrate the feasibility of a device that can non-invasively track changes in ICP associated with CNS infections. The proposed device measures the ICP based on high-resolution optical and ultrasound characterization of the carotid and cerebral arteries. The solution will be integrated into ambulatory devices worn on the head and/or around the neck.